Results 1 to 10 of about 1,092,864 (243)

Cancer-Specific Synthetic Lethality Between ATR and CHK1 Kinase Activities

Cell Reports, 2016
ATR and CHK1 maintain cancer cell survival under replication stress and inhibitors of both kinases are currently undergoing clinical trials. As ATR activity is increased after CHK1 inhibition, we hypothesized that this may indicate an increased reliance ...
José Manuel Calderón-Montaño, Ulrika Warpman Berglund, Mikael Altun   +2 more
exaly   +4 more sources

Cyclin-Dependent Kinases-Based Synthetic Lethality: Evidence, Concept, and Strategy

Acta Pharmaceutica Sinica B, 2021
Synthetic lethality is a proven effective antitumor strategy that has attracted great attention. Large-scale screening has revealed many synthetic lethal genetic phenotypes, and relevant small-molecule drugs have also been implemented in clinical ...
Qiaojun He, Wen Meng, Cheng-Liang Zhu
exaly   +3 more sources

Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. [PDF]

Signal Transduct Target Ther
Targeting synthetic lethal interactions has emerged as a promising strategy for cancer therapeutics, particularly by exploiting DNA damage response (DDR) pathways.
Camps-Fajol C, Minguillón J, Surrallés J.   +2 more
europepmc   +2 more sources

Synthetic lethality in cancer: mechanism exploration and therapeutic applications. [PDF]

Cell Commun Signal
Synthetic lethality (SL) is a genetic interaction phenomenon in which a cell can survive when either of two genes is individually mutated, but simultaneous disruption of both genes leads to cell death.
Zhao P, Wang P, Xu T, Chen L, Jia Q, Li M.   +5 more
europepmc   +2 more sources

Genome‐Scale Gene/Reaction Essentiality and Synthetic Lethality Analysis

Molecular Systems Biology, 2009
Synthetic lethals are to pairs of non‐essential genes whose simultaneous deletion prohibits growth. One can extend the concept of synthetic lethality by considering gene groups of increasing size where only the simultaneous elimination of all genes is ...
Costas D. Maranas, Patrick F Suthers
exaly   +2 more sources

Synthetic lethality in TP53-mutant acute myeloid leukemia. [PDF]

Blood Adv
Patel SA.
europepmc   +2 more sources

Research progress for the development of anti-tumor drugs based on synthetic lethality

生物医学转化, 2022
Synthetic lethality describes a phenomenon where mutation of any one of two non-lethal genes does not affect cell survival, whereas mutation of both genes significantly compromise cell viability.
Chen Pei, Mu Bo, Bin Huachao, Yang Shengyong   +3 more
doaj   +1 more source

Targeting synthetic lethality in colorectal cancer. [PDF]

Chin Med J (Engl)
Chen P, An J, Zhou J, Zou J, Peng C, Peng F.   +5 more
europepmc   +2 more sources

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer

BMC Cancer, 2023
Background Inhibitors of Poly (ADP-Ribose) Polymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising the DNA repair activity of cancer cells.
Shane O’Brien, Michael Butticello, Christine Thompson, Boris Wilson, Anastasia Wyce, Vivek Mahajan, Ryan Kruger, Helai Mohammad, Andy Fedoriw   +8 more
doaj   +1 more source

The tumor therapy landscape of synthetic lethality

Nature Communications, 2021
Various methods have been proposed to identify synthetic lethality interactions, but selective treatment opportunities for various tumors have not yet been explored. Here, the authors develop the Synthetic Lethality Knowledge Graph webserver (SLKG, http:/
Biyu Zhang, Chen Tang, Yanli Yao, Xiaohan Chen, Chi Zhou, Zhiting Wei, Feiyang Xing, Lan Chen, Xiang Cai, Zhiyuan Zhang, Shuyang Sun, Qi Liu   +11 more
doaj   +1 more source